Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775477 | 0.98 | ALDH1A1 (0.39) | THRBALDH1A1GBA1LMNASLC15A2 | |
| SCHEMBL5857936 | 0.82 | THRB (0.31) | THRBLMNA | |
| SCHEMBL7258080 | 0.82 | THRB (0.41) | THRBGBA1LMNACA2 | |
| SCHEMBL5485779 | 0.80 | THRB (0.44) | THRBALDH1A1GBA1LMNACA2 | |
| SCHEMBL5490761 | 0.80 | THRB (0.44) | THRBALDH1A1GBA1LMNACA2 | |
| SCHEMBL934065 | 0.80 | THRB (0.44) | THRBALDH1A1GBA1LMNACA2 | |
| SCHEMBL5490493 | 0.80 | THRB (0.44) | THRBALDH1A1GBA1LMNACA2 | |
| SCHEMBL1827086 | 0.80 | THRB (0.44) | THRBALDH1A1GBA1LMNACA2 | |
| SCHEMBL5488963 | 0.80 | THRB (0.44) | THRBALDH1A1GBA1LMNACA2 | |
| SCHEMBL1828702 | 0.80 | THRB (0.44) | THRBALDH1A1GBA1LMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237435-B1 | METABOLICALLY STABLE APELIN ANALOGS IN THE TREATMENT OF DISEASE MEDIATED BY THE APELIN RECEPTOR | INST NAT SANTE RECH MED (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | UNIVERSITE DE STRASBOURG (FR) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | APLNR, AVPR2, AVPR1A | THRB 778/4885ALDH1A1 1151/4885GBA1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.